iBio, Inc. (IBIO)
NASDAQ: IBIO · Real-Time Price · USD
1.404
-0.026 (-1.82%)
Aug 24, 2026, 1:36 PM EDT - Market open
iBio, Inc. Revenue
iBio, Inc. had revenue of $300.00K in the twelve months ending March 31, 2026, down -20.00% year-over-year. In the fiscal year ending June 30, 2025, iBio, Inc. had annual revenue of $400.00K with 77.78% growth.
Revenue (ttm)
$300.00K
Revenue Growth
-20.00%
P/S Ratio
236.80
Revenue / Employee
$15,000
Employees
20
Market Cap
69.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 400.00K | 175.00K | 77.78% |
| Jun 30, 2024 | 225.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 1.88M | -487.00K | -20.54% |
| Jun 30, 2021 | 2.37M | 733.00K | 44.75% |
| Jun 30, 2020 | 1.64M | -380.00K | -18.83% |
| Jun 30, 2019 | 2.02M | 1.57M | 354.50% |
| Jun 30, 2018 | 444.00K | 50.00K | 12.69% |
| Jun 30, 2017 | 394.00K | -554.00K | -58.44% |
| Jun 30, 2016 | 948.00K | -903.00K | -48.78% |
| Jun 30, 2015 | 1.85M | 1.65M | 802.93% |
| Jun 30, 2014 | 205.00K | -802.00K | -79.64% |
| Jun 30, 2013 | 1.01M | -270.00K | -21.14% |
| Jun 30, 2012 | 1.28M | 756.92K | 145.54% |
| Jun 30, 2011 | 520.08K | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | 1.18M | 189.55K | 19.20% |
| Jun 30, 2008 | 987.06K | 90.79K | 10.13% |
| Jun 30, 2007 | 896.27K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 59.43M |
| Spero Therapeutics | 47.00M |
| MediciNova | 920.48K |
| Cardiff Oncology | 508.00K |
| Serina Therapeutics | 130.00K |
IBIO News
- 4 days ago - iBio, Inc. Proxy statement: Proxy filing - Filings
- 20 days ago - iBio appoints Molly Carr as chief medical officer - TheFly
- 20 days ago - iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - iBio announces new preclinical data from IBIO-610 study - TheFly
- 7 weeks ago - iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study - GlobeNewsWire
- 2 months ago - iBio initiated with an Outperform at Raymond James - TheFly
- 2 months ago - iBio, Inc. Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - iBio to Participate in Upcoming Healthcare Investor Conferences - GlobeNewsWire